Stereotactic radiation for small liver cancer recurrence safety
Part of Cancer, Digestive system clinical trials.
This trial tests a precise type of radiation to treat small liver cancer that has come back after prior treatment. It aims to help with safety and long-term outcomes while protecting nearby organs and healthy liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your liver cancer (HCC) has come back, and there is no spread to lymph nodes or distant organs
- You previously had surgery or radiofrequency ablation, and the cancer did not return within 6 months
- Your tumor matches “early stage” limits: one size under 5 cm, or up to 3 spots each under 3 cm; no blood-vessel invasion and not outside the liver
- Your remaining healthy liver is sufficient for treatment (remnant liver volume beyond the target is > 700 ml)
- You must have enough blood counts and organ function (for example, hemoglobin ≥8, platelets ≥50, and good white blood cell/neutrophil levels)
- You can safely have radiation: good performance status (ECOG 0–1), Child-Pugh A–B liver function, and no nearby bowel within 0.5 cm
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving focused radiation therapy (SBRT) after liver surgery helps lower the chance of cancer coming back. It is for people whose surgery left a very small safety margin around the tumor.
This trial compares two treatments—radiation (SBRT) and surgery—for people with a small liver tumor (≤5 cm) that hasn't spread. The goal is to see which treatment works better.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
This Phase I study tests a specific radiation approach (vGRID SBRT) for hepatocellular carcinoma (and some mixed types) that is advanced and cannot be cured with surgery or transplant. It aims to control tumors while staying within safety limits for the liver and nearby organs.
This trial tests a treatment called radioembolization for small liver cancers. Radioembolization delivers tiny radioactive beads to the tumor, and the goal is to see if it helps shrink or control the cancer.
Hear when a new Carcinoma; Hepatocellular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.